- Home
- RNG vs CNTA Comparison
RNG vs CNTA Comparison
Compare RNG & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNG | CNTA |
|---|---|---|
| Founded | 1999 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.5B |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RNG | CNTA |
|---|---|---|
| Price | $33.15 | $39.64 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 9 |
| Target Price | $33.58 | ★ $42.00 |
| AVG Volume (30 Days) | 1.4M | ★ 4.2M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | ★ 176.19 | 29.13 |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $2,515,142,000.00 | $15,000,000.00 |
| Revenue This Year | $5.56 | N/A |
| Revenue Next Year | $4.56 | N/A |
| P/E Ratio | $76.93 | ★ N/A |
| Revenue Growth | ★ 4.78 | N/A |
| 52 Week Low | $21.91 | $10.95 |
| 52 Week High | $42.42 | $40.26 |
Technical Indicators
Market Signals| Indicator | RNG | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 38.65 | 76.90 |
| Support Level | $25.58 | $24.80 |
| Resistance Level | $39.74 | $40.26 |
| Average True Range (ATR) | 2.02 | 1.07 |
| MACD | -0.49 | 0.80 |
| Stochastic Oscillator | 1.48 | 96.49 |
Price Performance
Historical ComparisonAbout RNG RingCentral Inc.
RingCentral is a unified communications as a service, or UCaaS, provider. Its software helps users communicate and collaborate via voice, video, and messaging across all device types and all from one platform. RingCentral helps customers modernize and move from legacy on-premises systems to modern, cloud-based systems. Beyond its core RingCentral MVP solution, RingCentral also offers a cloud-based contact center solution, a stand-alone video meetings solution, and webinars.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.